KARYOPHARM THERAPEUTICS INC (KPTI)
US48576U1060 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 52.23M | 135.20M | 190.50M | 85.90M | 128.90M | |||
| Marketable Securities | 139.21M | 142.80M | 38.20M | 163.30M | 133.10M | |||
| Receivables | 26.96M | 47.10M | 22.50M | 12.90M | 7.90M | |||
| Inventories | 3.04M | 4.20M | 4.10M | 2.60M | 300.00K | |||
| Other Current Assets | 12.47M | 20.90M | 20.30M | 11.80M | 8.40M | |||
| Total Current Assets | 233.92M | 350.20M | 275.60M | 276.50M | 278.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 4.88M | 7.40M | 9.60M | 11.60M | 13.70M | |||
| Investments And Advances | N/A | N/A | 0.00 | 24.20M | 2.00M | |||
| Other Non-Current Assets | 1.64M | 600.00K | 20.10M | 700.00K | 700.00K | |||
| Total Non-Current Assets | 6.52M | 8.00M | 29.70M | 36.60M | 16.40M | |||
| TOTAL ASSETS | 240.44M | 358.20M | 305.30M | 313.10M | 295.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 64.70M | 61.30M | 71.40M | 54.80M | 42.50M | |||
| Accounts Payable | 3.12M | 2.80M | 1.60M | 4.50M | 1.00M | |||
| Other Current Liabilities | 1.65M | 1.80M | 700.00K | 900.00K | 2.80M | |||
| Total Current Liabilities | 69.48M | 65.90M | 73.70M | 60.20M | 46.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 303.40M | 302.80M | 302.30M | 191.00M | 183.40M | |||
| Other Non-Current Liabilities | 3.77M | 6.10M | 9.00M | 11.30M | 15.40M | |||
| Total Non-Current Liabilities | 307.17M | 308.90M | 311.30M | 202.30M | 198.80M | |||
| TOTAL LIABILITIES | 376.64M | 374.80M | 385.00M | 262.50M | 245.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.49B | -1.34B | -1.18B | -1.07B | -873.30M | |||
| Additional Paid In Capital | 1.35B | 1.33B | 1.10B | 1.12B | 923.10M | |||
| Common Shares | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -161.00K | -600.00K | 200.00K | 500.00K | 0.00 | |||
| Shares Outstanding | 114.92M | 113.20M | 75.70M | 73.90M | 65.40M | |||
| Tangible Book Value per Share | -1.19 | -0.15 | -1.05 | 0.68 | 0.76 | |||
| Total Shareholders' Equity | -136.21M | -16.70M | -79.70M | 50.50M | 49.80M | |||
| TOTAL LIABILITIES AND EQUITY | 240.44M | 358.20M | 305.30M | 313.10M | 295.00M | |||
| Statistics | ||||||||
| Debt/Equity | -2.23 | -18.13 | -3.79 | 3.78 | 3.68 | |||
| Current Ratio | 3.37 | 5.31 | 3.74 | 4.59 | 6.00 | |||
| Return On Assets (ROA) | -59.52% | -46.15% | -40.65% | -62.70% | -67.66% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | -388.71% | -400.80% | |||
All data in USD